Sellas Life Sciences: A 311% Run-Up Priced on Hope, Not Yet on Proof

Sellas stock soars 311% YTD on unconfirmed REGAL trial 80th event; analysts bullish, but official confirmation remains absent.

The arithmetic of biotech speculation can be brutal, and Sellas Life Sciences is currently living proof. The stock has surged 311 percent since the start of the year and more than sextupled over the past twelve months, yet the catalyst that would justify that trajectory—official confirmation that the pivotal REGAL trial has hit its 80th event—remains conspicuously absent from the company's own communications.

What the market is trading on instead is a cocktail of sector momentum, analyst conviction, and a single unverified German media report. That's a fragile foundation for a stock whose annualized volatility already runs at 96 percent.

The 78-to-80 Gap That Has the Market on Edge

The mechanics of the suspense are straightforward. Back in May, Sellas disclosed that the Phase 3 REGAL study, evaluating its GPS immunotherapy in leukemia patients, stood at 78 of 80 targeted events. The company said it would update investors once that threshold was crossed. Then, on August 18, licensing partner 3D Medicines announced that an arbitration award had been fully paid out and that the global 3D189 trial had reached 78 of 80 events.

Days later, a German outlet reported the milestone had actually been reached. Sellas has neither confirmed nor denied it. That silence has created a vacuum the market has been all too happy to fill with speculation—and with buying.

CEO Angelos Stergiou's most recent public statement, made in mid-August alongside second-quarter results, only added to the ambiguity: the company was approaching the predetermined 80th event, he said, a critical step toward the final efficacy analysis and, if positive, a potential BLA submission to the FDA. No timeline was attached.

Sector Tailwinds From Moderna and Merck

The broader backdrop has done Sellas no harm. A Phase 3 update from Moderna and Merck on their personalized mRNA cancer vaccine, Intismeran Autogene, in combination with Keytruda, showed improved disease-free survival in high-risk melanoma patients compared with Keytruda alone. The readout, released late last week, triggered a rally across oncology names as investors began re-rating immunotherapy plays with similar mechanisms.

For Sellas, the data isn't proof of concept for GPS—but it's a powerful signal that cancer vaccines as a drug class are gaining credibility. Maxim's analyst called the result "a win for cancer vaccines" and reaffirmed a Buy rating with a $30 price target on August 23.

Analyst Targets vs. the Reality of the Balance Sheet

Two houses are now firmly in the bullish camp. Alliance Global's James Molloy raised his price target from $25 to $35 on August 17, keeping a Buy rating. Maxim's $30 target sits alongside it. Both are well above the current share price, which traded at €12.00, up 3.0 percent on the day—though that followed a 3.7 percent decline to €11.65 the previous session, a dip with no identifiable company-specific trigger.

But these targets are conditional on a trial outcome that hasn't materialized yet. The financials offer a sobering counterpoint: Sellas posted a second-quarter loss of $0.05 per share, slightly missing consensus, with a net loss of $9.6 million on R&D expenses of $6.3 million and administrative costs of $4.4 million. Cash of roughly $138.3 million as of June 30 provides runway but cannot substitute for positive efficacy data.

The valuation math is equally demanding. At a market capitalization of approximately €2.44 billion, investors have already priced in a successful REGAL readout—and then some.

A Second Catalyst in the Shadows

Amid the REGAL drama, a second clinical program has been quietly advancing. The separate Phase 2 study of the GPS candidate in newly diagnosed AML patients, including early refractory cases following AZA/VEN treatment, has enrolled 28 of 80 planned patients. Patient selection relies on extensive transcriptomic, genomic, and proteomic modeling, the company says. Topline data are expected in the fourth quarter of 2026.

That timeline is distant, but it gives Sellas a second, independent shot at value creation—one that's been largely overshadowed by the REGAL speculation.

The Verdict: A Bet on Confirmation

The stock's recovery since the quarterly results speaks to genuine market optimism. But the gap between what the rumor mill claims and what Sellas has officially disclosed remains the central risk. Until the company itself confirms that the 80th event has been reached, every price move at these levels represents a wager on future news rather than a reaction to established fact.

The analyst community's conviction is understandable—provided REGAL delivers. But in the absence of an official announcement, the market is effectively trading on faith. For a stock that has already run 311 percent this year, the margin for disappointment is getting thinner by the day.